Physician profile
Pascal A Dauphin
NPI 1154324325
$924,785.41
in general payments reported to CMS, 2019-2025
61 companies · $134K in 2025
The $134K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287K · 2020: $93K · 2021: $54K · 2022: $146K · 2023: $113K · 2024: $97K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $215K · Travel and Lodging: $66K · Honoraria: $31K · Food and Beverage: $18K · Consulting Fee: $15K · Education: $96.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $214,717.50 |
| Travel and Lodging | $65,960.14 |
| Honoraria | $30,804.25 |
| Food and Beverage | $18,191.51 |
| Consulting Fee | $14,834.50 |
| Education | $96.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $441,149.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $180,804.12 | 2019-2025 | Evenity, Tepezza, Prolia |
| Astrazeneca Pharmaceuticals LP | $74,346.01 | 2019-2025 | Farxiga, Lokelma |
| Radius Health, INC. | $40,374.79 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $39,107.86 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $25,445.01 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22,000.25 | 2021-2025 | |
| Amarin Pharma, INC. | $21,847.94 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $20,592.77 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Esperion Therapeutics, INC. | $18,622.61 | 2020-2024 | Nexletol |
| Novo Nordisk INC | $14,025.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Clarus Therapeutics INC. | $12,078.71 | 2021 | |
| Corcept Therapeutics | $3,045.27 | 2019-2025 | Korlym |
| Valeritas, INC. | $2,002.06 | 2019 | |
| Senseonics, Incorporated | $1,200.00 | 2024-2025 | Eversense |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $782.16 | 2019-2025 | Omnipod |
| Beta Bionics, INC. | $719.88 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Boehringer Ingelheim Pharmaceuticals, INC. | $710.74 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Mannkind Corporation | $560.88 | 2019-2025 | Afrezza |
| Medtronic, INC. | $495.20 | 2021-2025 | Minimed 780g |
| Ascensia Diabetes Care US INC. | $396.30 | 2021-2024 | |
| Averitas Pharma INC. | $385.85 | 2024-2025 | Qutenza |
| Abbvie INC. | $348.62 | 2019-2025 | Synthroid |
| Abbott Laboratories | $331.39 | 2019-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $293.83 | 2022-2025 | |
| Antares Pharma, INC. | $233.51 | 2019-2025 | Xyosted |
| Zealand Pharma US, INC. | $232.02 | 2020-2022 | |
| Vistapharm, INC. | $220.42 | 2021 | |
| Cequr Corporation | $219.87 | 2023-2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $189.46 | 2019-2025 | Tirosint, Licart, Flector |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.99 | 2019-2023 | Cycloset |
| Sequel Med Tech, LLC | $171.59 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $155.08 | 2021-2024 | Crysvita |
| Currax Pharmaceuticals LLC | $134.00 | 2020-2022 | |
| Dexcom, INC. | $132.20 | 2022-2024 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $129.01 | 2023-2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $126.76 | 2022-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $123.93 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $91.17 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $90.13 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $78.23 | 2022-2025 | Unithroid |
| Madrigal Pharmaceuticals | $59.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Horizon Therapeutics Plc | $52.01 | 2022 | |
| Tolmar, INC. | $49.54 | 2023-2025 | Jatenzo |
| Opko Pharmaceuticals, LLC | $43.05 | 2025 | Rayaldee |
| Recordati_rare_diseases_inc. | $41.10 | 2023-2024 | Signifor Lar, Isturisa |
| Nevro Corp. | $40.90 | 2022-2024 | Senza |
| Companion Medical, INC. | $37.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $37.01 | 2019-2020 | |
| Pfizer INC. | $34.33 | 2019-2022 | |
| Intra-Sana Laboratories | $29.77 | 2023-2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Shire North American Group INC | $26.69 | 2019 | |
| Halozyme INC | $24.68 | 2023 | |
| Glaxosmithkline, LLC. | $23.31 | 2025 | Shingrix, Arexvy |
| Kyowa Kirin, INC. | $21.36 | 2023 | Crysvita |
| Nalpropion Pharmaceuticals LLC | $19.96 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.11 | 2020 | |
| Eisai INC. | $13.38 | 2019 | |
| Aytu Biopharma, INC. | $13.33 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $13.31 | 2024 | |
| Sun Pharmaceutical Industries INC. | $12.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascal Dauphin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.